Last February, Carolyne Eagan’s mother was suddenly stricken with an excruciatingly painful condition called trigeminal neuralgia, which prevented her from eating, talking or drinking without triggering a flare of pain in her head. Eagan gathered up her mom’s medications and got into the ambulance with her, feeling increasingly distressed as she wasn’t able to answer […]
“What if I told you at least one in four members of your benefits plan has an unresolved health risk?” asked Radpay, the president of HumanisRx, during Benefits Canada‘s 2021 Tech Insights: Spring Edition conference. In a study in partnership with Munich Re, HumanisRx reviewed the insurer’s claims history experience for 85,000 plan members and […]
The New Brunswick government is expanding the use of biosimilars for certain chronic conditions in its public drug plans. Approximately 3,000 beneficiaries of the province’s drug plans who are living with diseases such as inflammatory arthritis, inflammatory bowel disease, diabetes and psoriasis will have until Nov. 30 to switch from a biologic to the biosimilar […]
While a national pharmacare program is yet to be revealed by the federal government, any future plan should contain provisions for all costly treatments and not just rare diseases, says Jennifer Schmidt, a principal at Mercer Canada. Read: Federal budget highlights national childcare system, extension of pandemic subsidies This week’s federal budget announcement contained only […]
While drug plan costs are increasing for plan sponsors, the causes for these increases may depend on which part of Canada a plan sponsor resides in, says Philippe Laplante, a principal responsible for the group benefits practice in Eckler Ltd.’s Montreal office. Over the past three years in Quebec, the average annual increase of recommended pricing […]
Growth in chronic disease and increased drug claims are two of the key factors driving up the cost of private health benefit plans, according to a new report by Innovative Medicines Canada. It found that chronic diseases accounted for 68 per cent of drug plan claims costs and 79 per cent of growth. Claims costs […]
From a plan-manager perspective, eight per cent of plan members are living with diabetes, said Dr. Bruce Perkins, professor in the division of endocrinology and metabolism at the University of Toronto, during Benefits Canada’s Face to Face Drug Plan Management Forum on Dec. 9, 2020. He said risk-factor management is necessary when it comes to […]
Plan sponsors with growing concerns about benefits plan sustainability should focus on a few strategic pharmacy benefits plan issues, said Mark Rolnick, executive vice-president of pharmacy innovation and patient experience at Green Shield Canada, during a session at Benefits Canada’s Face to Face Drug Plan Management Forum on Dec. 9, 2020. He recommended that plans […]
Employers that don’t cover obesity drugs should ask themselves why, said Noel McKay, principal consultant at Cowan Insurance Group, during Benefits Canada’s Face to Face Drug Plan Management Forum on Dec. 9, 2020. “Is the risk of driving up benefits costs the reason? If so, I don’t think you have to fear it. Maybe two […]
Despite concerns Canadian drug prices are skyrocketing, the Patented Medicines Price Review Board, Canada’s price regulator, has ensured costs for patented drugs haven’t increased more than the Canadian Consumer Price Index in close to 30 years, said Wayne Critchley, Global Public Affairs’ senior associate of health and life sciences, during Benefits Canada’s Face to Face […]